JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO ® (omalizumab-igec) as the first and only biosimilar designated ...
Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved Omlyclo ® ...
Celltrion said on the 25th that Omlyclo (OMLYCLO), a treatment for chronic spontaneous urticaria launched in Europe in Sep., has been released in major countries, including Germany, Spain, the United ...
Please provide your email address to receive an email when new articles are posted on . Omlyclo is the first interchangeable biosimilar to omalizumab (Xolair; Genentech, Novartis). Omlyclo was ...
INCHEON, South Korea, Dec. 1, 2025 /PRNewswire/ -- Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO ® (omalizumab-igec), the first ...
TORONTO--(BUSINESS WIRE)--Celltrion today announced that Health Canada has approved Omlyclo ™, a biosimilar referencing Xolair ®. Omlyclo ™ is approved for the treatment of adults and adolescents with ...
Omlyclo, a biosimilar to Xolair, is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, immunoglobulin E-mediated food allergies, and chronic ...
Celltrion said on the 24th that it received additional approval from the Ministery of Food and Drug Safety for the auto-injector (AI) formulation of the allergy disease treatment "OMLYCLO." The ...
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global ...
The European Commission (EC) has approved Celltrion’s Omlyclo (CT-P39), an omalizumab biosimilar referencing Novartis and Genentech’s Xolair, for a range of immunological conditions. Omlyclo, which ...
Please provide your email address to receive an email when new articles are posted on . Omlyclo is approved to treat the same four conditions as omalizumab. There are now three doses/solutions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results